Frontage Holdings Corporation (Frontage) reported a robust first-half performance for the six months ended 30 June 2026, underpinned by double-digit revenue growth, margin resilience and a sharp rebound in profitability.
Financial Highlights • Revenue rose 17.1% year on year to USD 148.20 million, supported by solid demand across drug development and laboratory testing services. • Gross profit increased 7.4% to USD 37.90 million; gross margin contracted to 25.6% from 27.9% due to a shift in revenue mix and higher input costs. • EBITDA grew 17.4% to USD 31.70 million, maintaining a stable margin of 21.4%. Adjusted EBITDA advanced 22.8% to USD 34.50 million, with margin expanding to 23.3%. • Net profit surged 134.5% to USD 6.79 million, lifting net margin to 4.6% from 2.3%. Adjusted net profit climbed 74.0% to USD 13.44 million, equivalent to a 9.1% margin. • Basic and diluted EPS doubled to USD 0.0033; adjusted EPS reached USD 0.0066. • The Board declared no interim dividend.
Operational Drivers • Laboratory testing revenue jumped 26.9% to USD 84.86 million, representing 57% of total sales, reflecting heightened demand for bioanalytical and biomarker services. • Drug development revenue grew 12.0% to USD 46.76 million, while drug discovery and pharmaceutical product development contributed USD 12.03 million and USD 4.55 million respectively. • Geographically, North America and Europe generated USD 106.30 million (+7.8%), while China delivered USD 41.89 million (+43.6% in RMB terms), buoyed by the March 2026 acquisition of Teddy Clinical Research Laboratory (Teddy Lab). Revenue from other regions more than doubled to USD 10.97 million.
Margin Dynamics • North America and Europe gross margin narrowed to 27.3% (1H25: 30.4%) due to a higher share of lower-margin projects and increased costs. • China gross margin improved to 21.3% (1H25: 19.2%), aided by the integration of higher-margin Teddy Lab operations and better capacity utilisation.
Cost & Expense Trends • Cost of services rose 20.8% to USD 110.30 million in line with revenue growth and the Teddy Lab consolidation. • Selling and marketing expenses eased 7.0% to USD 3.96 million, reflecting efficiency gains. • Administrative expenses fell 9.1% to USD 18.91 million; excluding non-cash items and M&A-related costs, underlying administrative spend declined 10.0%. • Finance costs decreased 16.7% to USD 3.49 million following repayment of higher-rate debt.
Balance Sheet & Cash Flow • Cash and cash equivalents stood at USD 34.56 million (31 Dec 2025: USD 36.30 million). • Net cash from operations reached USD 25.66 million, while investment outflows of USD 39.97 million reflected capital expenditure and the Teddy Lab purchase. • Interest-bearing borrowings increased to USD 95.99 million; gearing rose to 29.2% (31 Dec 2025: 25.4%).
Strategic Developments • Completion of the RMB 270.00 million acquisition of Teddy Lab expands Frontage’s central lab capabilities in China, particularly in cell and gene therapy, vaccines and radiopharmaceuticals, and lifts the global site count to 25. • Continued investment in AI-assisted workflows and laboratory automation supports efficiency and scale across discovery, development and testing services. • Contract future revenue (backlog) climbed 34.2% year on year to USD 543.20 million.
Outlook Frontage intends to leverage its broadened global footprint and integrated service platform to capture opportunities in the contract research organisation market, which Fortune Business Insights estimates will reach USD 199.28 billion by 2034. The company will focus on high-growth therapeutic modalities, ongoing digital transformation and selective acquisitions to sustain momentum.